Esperion Therapeutics/ESPR

$2.55

1.59%
-
1D1W1MYTD1YMAX

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

Ticker

ESPR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sheldon Koenig

Employees

240

Headquarters

Vero beach, United States

ESPR Metrics

BasicAdvanced
$464.48M
Market cap
-
P/E ratio
-$2.37
EPS
0.82
Beta
-
Dividend rate

What the Analysts think about ESPR

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
190.59% upside
High $16.00
Low $2.90
$2.55
Current price
$7.41
Average price target

ESPR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-121.53% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$33.9M
31.91%
Net income
$-41.2M
-17.43%
Profit margin
-121.53%
-37.41%

ESPR Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.63%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.79
-$0.46
-$0.37
-$0.50
-
Expected
-$0.65
-$0.61
-$0.43
-$0.48
-$0.00
Surprise
21.1%
-24.75%
-14.4%
3.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Esperion Therapeutics stock

Buy or sell Esperion Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing